Breaking News Instant updates and real-time market news.

AAPL

Apple

$156.07

-2.66 (-1.68%)

, BSTI

Best Inc.

16:16
09/20/17
09/20
16:16
09/20/17
16:16

On The Fly: Top stock stories for Wednesday

Stocks were largely on hold for another morning in advance of the Federal Reserve's policy announcement. While the Fed's plans were largely as previewed, the initial reaction of the major averages was to selloff a bit as bond yields rose. The averages regained what was lost in the brief pullback as Fed Chair Janet Yellen spoke to reporters following the policy decision. The Dow finished with a mild advance while the S&P eked out a small gain, but both were good enough to set new records. The Nasdaq was the worst performer of the day, as a number of big name tech stocks were weak. ECONOMIC EVENTS: The Federal Reserve's monetary policy announcement went largely as expected, as the central bank opted not to raise rates yet but signaled a hike is still projected at its December meeting. Also as expected, the Fed said it will initiate its balance sheet normalization program in October as it begins to shrink its $4.5T securities portfolio. U.S. existing home sales dropped 1.7% to a 5.35M rate in August, which was weaker than expected, though some of that may be due to a hurricane effect. EIA inventory data showed a 4.6M barrel rise in crude oil stocks, versus the consensus forecast for a build-up of 3.86M barrels. COMPANY NEWS: Shares of Apple (AAPL) slid nearly 2% following reports of Apple Watch connectivity issues and somewhat disappointing reviews for the upcoming device. Meanwhile, Rosenblatt analyst Jun Zhang said checks suggest iPhone 8 preorder volume is below that seen for prior models, possibly because buyers are holding out for the delayed, premium iPhone X... FedEx (FDX) reported much lower than expected Q1 earnings and cut its fiscal year profit outlook due to the estimated full-year impacts of the TNT Express cyberattack. However, such a guidance cut had been largely telegraphed by analysts leading up to the call and shares advanced 2% following last night's report. Conversely, Adobe (ADBE) beat earnings expectations but its shares were weighed down by weaker than expected Experience Cloud bookings in Q3. Adobe slid over 4% on the heels of its report. Meanwhile, General Mills (GIS), which backed it full year earnings growth view but reported a miss for its first quarter, ended the trading day nearly 6% lower... Today was a busy day for IPOs. Shares of Best Inc. (BSTI), a company backed by Alibaba (BABA), jumped in their market debut, a day after the company slashed its expected pricing range. The South American Despegar.com (DESP), the biotech Celcuity (CELC), China-based Zai Lab (ZLAB) and the gene therapy micro-cap Krystal Biotech (KRYS) were the other initial public offerings this morning. MAJOR MOVERS: Among the notable gainers was Copart (CPRT), which gained 4% after reporting Q4 earnings that were slightly better than expected. Also higher was Alnylam Pharmaceuticals (ALNY), which jumped 52% after reporting that its Apollo Phase 3 trial of a rare-disease drug met its primary target and all of its secondary goals. Consequently, Ionis Pharmecuticals (IONS) was among the noteworthy losers, dropping about 9% after competitor Alnylam's positive news. Also lower was Bed Bath & Beyond (BBBY), which fell 16% after the retailer reported worse than expected earnings and cut its full-year profit view. INDEXES: The Dow rose 41.79, or 0.19%, to 22,412.59, the Nasdaq dropped 5.28, or 0.08%, to 6,456.04, and the S&P 500 slipped 1.59, or 0.06%, to 2,508.24.

AAPL

Apple

$156.07

-2.66 (-1.68%)

BSTI

Best Inc.

BABA

Alibaba

$177.95

-2.12 (-1.18%)

FDX

FedEx

$220.53

4.531 (2.10%)

ADBE

Adobe

$149.96

-6.64 (-4.24%)

GIS

General Mills

$52.17

-3.215 (-5.81%)

CPRT

Copart

$33.86

1.32 (4.06%)

ALNY

Alnylam

$113.78

38.7408 (51.63%)

IONS

Ionis Pharmaceuticals

$53.88

-5.19 (-8.79%)

BBBY

Bed Bath & Beyond

$22.74

-4.29 (-15.87%)

DESP

Despegar.com

CELC

Celcuity

$14.29

14.289 (1,428,900.00%)

ZLAB

Zai Lab

KRYS

Krystal Biotech

  • 20

    Sep

  • 20

    Sep

  • 20

    Sep

  • 20

    Sep

  • 21

    Sep

  • 25

    Sep

  • 22

    Oct

  • 20

    Sep

  • 20

    Sep

  • 20

    Sep

  • 20

    Sep

  • 20

    Sep

AAPL Apple
$156.07

-2.66 (-1.68%)

09/20/17
RSBL
09/20/17
NO CHANGE
RSBL
Apple iPhone 8 preorder volume below prior models, says Rosenblatt
Rosenblatt analyst Jun Zhang said checks indicate about 1.5M iPhone 8 preorders on JD.com (JD) in the first three days, versus 3.5M for the iPhone 7 in the first three days. He also thinks China Mobile's (CHL) iPhone 8 preorder volumes are around 1M units, compared to 2.5M iPhone 7 units and 3.5M iPhone 6 units, for the first three days. For the U.S., Zhang said initial feedback also suggests iPhone 8 preorder volume below the iPhone 7 and iPhone 6. The analyst remains concerned iPhone 8 production plan of approximately 70M units for second half 2017 might need to be cut and the iPhone X production ramp might not be able to meet demand for the December and March quarters.
09/19/17
MSCO
09/19/17
NO CHANGE
Target $194
MSCO
Overweight
Apple price target raised to $194 on higher average prices at Morgan Stanley
Morgan Stanley analyst Katy Huberty said its aspirational brand, high loyalty, and the weaker U.S. dollar all contribute to letting Apple increase prices without hurting demand, calling an uplift in average selling prices for iPhones the "key takeaway" from Apple's recent product launch event. The analyst, who noted that innovation-led price increases historically boost, rather than hurt, Apple demand, increased her FY18 EPS estimate for Apple and raised her price target on the stock to $194 from $182. Huberty keeps an Overweight rating on Apple shares.
09/15/17
09/15/17
UPGRADE
Target $62.5

Outperform
Qualcomm upgraded to Outperform on 3D sensing opportunity at Northland
As previously reported, Northland analyst Tom Sepenzis upgraded Qualcomm (QCOM) to Outperform from Market Perform on expectations for market share gains in 2018, particularly at the high end, as he sees the company and partner Himax (HIMX) as well positioned to become the "de facto leading 3D sensing solution" with Android manufacturers who follow the lead of Apple's (AAPL) new iPhone X. From what he understands, handset makers that want to use its SLiM structured light solution will have to use Qualcomm's next generation Snapdragon chipset too, he tells investors. Sepenzis keeps a $62.50 price target on Qualcomm shares.
09/15/17
KEYB
09/15/17
NO CHANGE
Target $62
KEYB
Overweight
Criteo has workaround to Apple cookie disabler, says KeyBanc
KeyBanc analyst Andy Hargreaves recommends buying Criteo (CRTO) after the company at an event yesterday detailed its Commerce Marketing Platform, which aggregates online and offline data across partners to create a "Shopper Graph." The product has the potential to create new product areas, deepen partnerships and expand Criteo's "moat," Hargreaves tells investors in a research note. The stock has been weak on Apple's (AAPL) upcoming Intelligent Tracking Prevention rollout, which attempts to disable third-party tracking cookies after 24 hours, Hargreaves points out. He sees the issue as transitory, however, noting Criteo has a workaround that he believes will prove effective with direct publisher relationships. The analyst views Criteo's risk/reward as attractive and keeps an Overweight rating on the name with a $62 price target.
BSTI Best Inc.

BABA Alibaba
$177.95

-2.12 (-1.18%)

09/01/17
MKMP
09/01/17
NO CHANGE
Target $76
MKMP
Buy
MKM ups Altaba price target to $76 on higher Alibaba outlook
MKM Partners analyst Rob Sanderson raised his price target for Altaba (AABA) shares to $76 from $62 to reflect a higher outlook for the value of the company's Alibaba (BABA) stake. His new sum-of-the-parts valuation embeds a 12-month price target for Alibaba of $220, current value for other assets and the full 40% tax liability. The pretax value of Altaba's assets is now $95 per share, Sanderson tells investors in a research note. He sees tax efficiencies on the stake, upside in the value of Yahoo Japan (YAHOY) and sale of patents in excess of fair value as potential upside scenarios for Altaba. The analyst keeps a Buy rating on the shares. Altaba closed yesterday down 8c to $64.08.
09/06/17
JPMS
09/06/17
NO CHANGE
Target $200
JPMS
Overweight
Alibaba price target lowered to $200 from $205 at JPMorgan
JPMorgan analyst Alex Yao lowered his price target for Alibaba Group Holding to $200 saying he expects the company's s FY18 non-GAAP EBITDA margin to decline to 43% from 47% in FY17 due to investments across B2C promotions, New Retail and video content. The analyst sees a "mixed outlook" for return on investment, but believes the investments "pave the way for long-term sustainable earnings growth." Yao keeps an Overweight rating on Alibaba.
09/07/17
DBAB
09/07/17
NO CHANGE
Target $199
DBAB
Buy
Alibaba price target lowered to $199 from $208 at Deutsche Bank
Deutsche Bank analyst Alan Hellawell lowered his price target for Alibaba shares to $199 after recalibrating his estimates to reflect higher investment for the rest of fiscal year 2018. The analyst reduced his profit estimates to reflect Alibaba's intention to grow B2C market share and rising video spend. Hellawell maintains his FY18 revenue growth estimate of 48.5% on "continuously improving ad personalization and other data analytics tools increasing merchant ROI." The analyst reiterates a Buy rating on Alibaba.
09/12/17
MSCO
09/12/17
NO CHANGE
MSCO
Augmented Reality the next 'killer app' to power Apple, says Morgan Stanley
A team of Morgan Stanley analysts including Katy Huberty, Brian Nowak and Grace Chen, among others, state in a new note to investors that they view Augmented Reality, or AR, as a revolutionary trend that can be "the next killer app" to extend the life of the smartphone market and accelerate device upgrades, led by Apple's (AAPL) iPhone. The analysts, who compare the impact of AR to the launch of Apple's App Store nearly a decade ago, add that they "don't expect the Android ecosystem to stand still in response." Huberty and the team raised the firm's "bull case" valuation of Apple, which they see taking the lead in AR, to $253 from $203. While they see Apple as "the clear leader" in AR, Google (GOOG) and Tencent (TCEHY) are also well-positioned and "interesting use cases" in e-commerce could benefit Alibaba (BABA) and Amazon (AMZN), they add.
FDX FedEx
$220.53

4.531 (2.10%)

09/15/17
09/15/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Equifax (EFX) downgraded to Hold from Buy at Argus with analyst Jasper Hellweg citing news of a major hack on the company's data that could have lasting effects. 2. FedEx (FDX) downgraded to Neutral from Buy at UBS with analyst Thomas Wadewitz citing TNT issues following the cyber-attack in June that knocked out multiple systems. 3. Carnival (CCL) downgraded to Neutral from Outperform at Credit Suisse with analyst Tim Ramskil saying he is worried that his estimate of absolute industry capacity growth in 2018-2021 is double that of the last five years. 4. American Airlines (AAL), United Continental (UAL), and Spirit Airlines (SAVE) were downgraded to Neutral from Overweight at JPMorgan. 5. Acuity Brands (AYI) downgraded to Market Perform from Outperform at Wells Fargo with analyst Richard Kwas saying his firm's electrical channel checks indicate the 8% consensus organic revenue growth estimate for FY18 does not have upside. The analyst thinks shares are likely range-bound in the $160-$200 range "for the time being." He believes a "material step up" in tiered solutions growth is needed for gross margin to outperform expectations. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/20/17
BMOC
09/20/17
NO CHANGE
BMOC
FedEx cyberattack 'transient,' says BMO Capital
BMO Capital analyst FadiChamoun,says that the cyberattack on FedEx is a "transient" issue, and the analyst thinks that the company's fundamentals remain "solid" in the wake of its Q1 results. The analyst continues to believe that its EPS can rise significantly in the next three years, and keeps a $216 price target and an Outperform rating on the shares.
09/20/17
FBCO
09/20/17
NO CHANGE
Target $233
FBCO
Outperform
FedEx price target lowered to $233 from $242 at Credit Suisse
Credit Suisse analyst Allison Landry lowered her price target for FedEx to $233 from $242 on weaker than expected results and guidance. The analyst reiterates an Outperform rating on the shares.
09/20/17
LOOP
09/20/17
NO CHANGE
LOOP
FedEx price target raised to $260 from $250 at Loop Capital
Loop Capital analyst Rick Paterson raised his price target on FedEx after the company reported much lower than expected Q1 EPS. The analyst blamed the miss on a cyberattack and Hurricane Harvey. The analyst notes that the company expects FedEx Ground's operating income to rise this year, while it reiterated its operating income target for its Express unit. The analyst says that the stock "will have no choice" but to rise if the company continues to reiterate the latter target. He keeps a Buy rating on the shares.
ADBE Adobe
$149.96

-6.64 (-4.24%)

09/20/17
FBCO
09/20/17
NO CHANGE
Target $170
FBCO
Outperform
Adobe price target raised to $170 from $160 at Credit Suisse
Credit Suisse analyst Michael Nemeroff raised his price target for Adobe to $170 from $160 following quarterly results. The analyst remains positive on Adobe's business overall, and argues that investor sentiment heading into its Q3 print was very high, possibly too strong, which could cause the shares to dip in the near-term, which he would see as a good buying opportunity. Nemeroff reiterates an Outperform rating on the shares.
09/20/17
KEYB
09/20/17
NO CHANGE
Target $174
KEYB
Overweight
Adobe should be bought on weakness, says KeyBanc
KeyBanc analyst Brent Bracelin remains positive on Adobe based on best-in-class free cash flow growth of 41% year over year, attractive growth prospects for a $8B revenue franchise addressing a $60B TAM, and a dominant market position in Creative Cloud with substantial share gain potential in Marketing and Customer Experience segments. The analyst recommends buying Adobe on weakness as free cash flow should exceed $8 per share within two years. He reiterates an Overweight rating and $174 price target on the shares.
09/20/17
WELS
09/20/17
NO CHANGE
Target $145
WELS
Market Perform
Adobe price target raised to $145 from $127.50 at Wells Fargo
Wells Fargo analyst Philip Winslow raised his price target for Adobe to $145 from $127.50 following Q3 results. The analyst reiterates a Market Perform rating on the shares.
09/20/17
RBCM
09/20/17
NO CHANGE
RBCM
Adobe shares should be bought on weakness, says RBC Capital
RBC Capital analyst Ross MacMillan says that Adobe's digital marketing revenue came in below expectations due to longer sales cycles. However, he doesn't think the miss suggests that the business is facing "structural/competitive issues," and he believes that the company's "earnings growth remains largely intact." The analyst recommends buying the stock on weakness.
GIS General Mills
$52.17

-3.215 (-5.81%)

07/26/17
JEFF
07/26/17
NO CHANGE
Target $50
JEFF
Buy
Hain Celestial management would sell at right price, says Jefferies
After hosting investor meetings with management, Jefferies analyst Akshay Jagdale performed additional work to quantify Hain Celestial's (HAIN) strategic value. The analyst believes there would be "significant strategic interest" in Hain and that management "is a willing seller" at the right price. A deal for Hain makes the most sense for Pinnacle Foods (PF), Jagdale tells investors in a research note. He analyzed five scenarios in which hypothetical strategic buyers acquire Hain for $70 per share. The organic and natural products company closed yesterday up 1c to $43.80. Jagdale estimates that by year three, the deal would be 8% accretive to Pinnacle's earnings, 4% to General Mills' (GIS) and Conagra Brands' (CAG), 1.4% to Campbell Soup's and dilutive to Kellogg's (K). The analyst sees limited downside to shares of Hain and keeps a Buy rating on the stock with a $50 price target.
05/24/17
PIPR
05/24/17
INITIATION
Target $57
PIPR
Underweight
General Mills initiated with an Underweight at Piper Jaffray
Piper Jaffray analyst Michael Lavery initiated General Mills with an Underweight and a $57 price target saying international sales highlights potential risks to estimates. The analyst sees international sales below consensus by $70M-$75M, comparable to the Q4 2016 one-time gain from an accounting change and an extra month of European yogurt sales. Lavery also said said scanner data for 6 of its 7 largest categories are down by more than 3% and shifts in the retail environment present risks for center-store processed food manufacturers.
06/26/17
JPMS
06/26/17
NO CHANGE
JPMS
JPMorgan sees Kraft, Conagra, Dean rallying on Nestle speculation
JPMorgan analyst Ken Goldman expects Third Point's desire for Nestle (NSRGY) to divest assets to have an impact on shares of U.S. food producers. The analyst expects shares of Kraft Heinz (KHC), Conagra Brands (CAG) and Dean Foods (DF) to rally today on hopes of a potential accretive deal for some of Nestle's assets. The analyst thinks General Mills (GIS) shares may drop slightly on speculation that Nestle sells Cereal Partners Worldwide, which he believes would hinder the company's ability to grow cereal internationally. General Mills has a global partnership with Nestle via Cereal Partners Worldwide. Goldman also thinks Pinnacle Foods (PF) could trade down slightly with Conagra having "another potential dance partner" to do a deal.
09/06/17
FBCO
09/06/17
NO CHANGE
Target $43
FBCO
Underperform
Campbell Soup, Wal-Mart still negotiating, says Credit Suisse
Following up on Campbell Soup's (CPB) public disagreement in the soup category with Wal-Mart (WMT), Credit Suisse analyst Robert Moskow says the dispute specifically relates to Wal-Mart's demands for lower everyday price points on Campbell's condensed soup products. While this dispute does not appear to involve General Mills' (GIS) Progresso brand or the ready-to-serve category at this time, the analyst notes that Wal-Mart presumably could threaten to give more shelf space to General Mills or its Great Value brand at Campbell's expense. Campbell and Wal-Mart are still negotiating, Moskow points out, adding that it may be a good thing for the stock if Campbell can get Wal-Mart to agree to a compromise. The analyst reiterates an Underperform rating and $43 price target on Campbell's shares.
CPRT Copart
$33.86

1.32 (4.06%)

11/23/16
BARD
11/23/16
NO CHANGE
Target $60
BARD
Outperform
Copart weakness a buying opportunity, says Baird
Baird analyst Craig Kennison said Copart reported impressive Q1 results but the market may have missed it. The analyst noted improved revenues fueled by accidents, higher severity and numerous catastrophes, and market share gains. Kennison raised his estimates and price target and believes investors misunderstand the company dynamics, which will create a trading opportunity. Kennison recommend buying shares on a dip, reiterated his Outperform rating, and raised his price target to $60 from $56 on Copart shares.
09/07/17
SPHN
09/07/17
DOWNGRADE
Target $48
SPHN
Equal Weight
KAR Auction downgraded to Equal Weight from Overweight at Stephens
Stephens analyst Ben Bienvenu downgraded KAR Auction (KAR) to Equal Weight from Overweight, stating that while vehicle damage from Hurricane Harvey likely creates a surge of volume, the volume should also have significant costs that put pressure on profitability. He lowered his price target on KAR Auction to $48 from $51. He also noted that Hurricane Harvey's impact could limit share price upside over the next few quarters for fellow salvage auction operator Copart (CPRT).
11/23/16
SPHN
11/23/16
DOWNGRADE
SPHN
Equal Weight
Copart downgraded to Equal Weight from Overweight at Stephens
11/23/16
11/23/16
DOWNGRADE
Target $59

Equal Weight
Copart downgraded to Equal Weight at Stephens
As previously reported, Stephens analyst Ben Bienvenu downgraded Copart to Equal Weight from Overweight as valuation could be tough to sustain. While the analyst likes the fundamentals of this story and continues to think the company will produce strong results, he believes that risk/reward is more balanced given the stock's substantial appreciation so far this year and the more difficult comparisons that are ahead. Bienvenu also lowered his price target on the shares to $59 from $61.
ALNY Alnylam
$113.78

38.7408 (51.63%)

09/20/17
PIPR
09/20/17
NO CHANGE
Target $116
PIPR
Overweight
Piper ups Alnylam target to $116 on positive patisiran data
Piper Jaffray analyst Edward Tenthoff raised his price target for Alnylam Pharmaceuticals (ALNY) to $116 from $110 after the company reported positive Phase III Apollo data on patisiran in 225 hereditary ATTR amyloidosis with olyneuropathy patients. Importantly, patisiran demonstrated a clean safety profile that differentiates from Ionis Pharmaceuticals' (IONS) inotersen, Tenthoff tells investors in a research note. He reiterates an Overweight rating on Alnylam. The stock in morning trading is up 41%, or $30.93, to $105.97. Ionis is down 8% to $54.10.
09/20/17
JEFF
09/20/17
NO CHANGE
Target $102
JEFF
Buy
Jefferies says Alnylam patisiran results a 'best-case scenario'
Jefferies analyst Maury Raycroft views Alnylam's (ALNY) topline results from the Apollo trial of patisiran as "highly positive" and a "best-case scenario" from a competitive perspective. The lack of any notable safety signal and benefit on secondary endpoints further distinguishes this "as a clear win" and should help the company's negotiations with payers, he tells investors. Patisiran appears to have a superior safety profile to Ionis' (IONS) inotersen, added Raycroft, who has a Buy rating and $102 price target on Alnylam shares.
09/20/17
JMPS
09/20/17
NO CHANGE
Target $128
JMPS
Outperform
Alnylam price target raised to $128 from $101 at JMP Securities
JMP Securities analyst Michael King, Jr. raised his price target on Alnylam to $128 from $101 after the company reported that its Apollo trial of patisiran hit its primary and all of its secondary endpoints. Not only did the trial show that patisiran can reverse disease progression, the drug's safety profile is "very encouraging," giving it the potential to be a "best-in-class treatment," said the analyst, who keeps an Outperform rating on the stock.
09/20/17
NEED
09/20/17
NO CHANGE
Target $125
NEED
Buy
Alnylam price target raised to $125 from $85 at Needham
IONS Ionis Pharmaceuticals
$53.88

-5.19 (-8.79%)

09/20/17
PIPR
09/20/17
NO CHANGE
Target $110
PIPR
Overweight
Alnylam study 'hits with clean safety,' says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff reiterates an Overweight rating on Alnylam Pharmaceuticals (ALNY) with a $110 price target saying the Apollo study hit "with clean safety." The analyst believes the clean safety profile differentiates Alnylam's patisiran from competitor Ionis Pharmaceuticals' (IONS) inotersen. Alnylam retains full rights to patisiran in the U.S. and Europe and is partnered with Sanofi for rest of world, Tenthoff tells investors in a research note. Alnylam shares are up 21% to $90.51 in premarket trading while Ionis is down 8% to $54.50.
09/20/17
EVER
09/20/17
NO CHANGE
Target $65
EVER
Outperform
Ionis story still about SMA launch, Huntington's data, says Evercore ISI
Evercore ISI Joshua Schimmer said he wouldn't be surprised to see Ionis (IONS) shares fall 5%-10% after competitor Alnylam (ALNY) reported positive results from the Phase 3 APOLLO study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy. However, he believes the Ionis story continues to be about the Spinraza launch in SMA with partner Biogen (BIIB) and its Huntington's data later this year. He keeps an Outperform rating and $65 price target on Ionis shares, which are down nearly 9% in early trading to $53.92.
BBBY Bed Bath & Beyond
$22.74

-4.29 (-15.87%)

09/20/17
DBAB
09/20/17
NO CHANGE
Target $21
DBAB
Hold
Bed Bath & Beyond price target lowered to $21 from $31 at Deutsche Bank
Deutsche Bank analyst Mike Baker cut his price target for Bed Bath & Beyond shares to $21 saying last night's Q2 results were "tougher than even cautious views." The stock in afternoon trading is down 16%, or $4.40, to $22.64. The analyst credits management for continuing to proactively invest in an attempt to compete in a changing home goods landscape, but points out the retailer's "precipitous" margin declines continue. In an intraday research note titled "Two Steps Back, One Step Forward," Baker keeps a Hold rating on Bed Bath & Beyond.
09/20/17
FBCO
09/20/17
NO CHANGE
Target $25
FBCO
Neutral
Bed Bath & Beyond price target lowered to $25 from $33 at Credit Suisse
Credit Suisse analyst Seth Sigman lowered his price target for Bed Bath & Beyond to $25 from $33 after Q2 results came in well below expectations due to weaker store comps and gross margin, and higher expenses. The analyst notes that while Bed Bath & Beyond is clearly not alone in these challenges, it is difficult to "see the light at the end of the tunnel." Sigman reiterates a Neutral rating on the shares.
09/20/17
MSCO
09/20/17
NO CHANGE
Target $23
MSCO
Underweight
Bed Bath trends getting worse more quickly than expected, says Morgan Stanley
Morgan Stanley analyst Simeon Gutman noted that Bed Bath & Beyond's store traffic worsened in Q2 compared to the prior quarter and its gross margin contracted 100 basis points, neither of which is a trend he sees improving given the competitive environment in home furnishings. The analyst, who keeps an Underweight rating on Bed Bath, lowered his price target on the stock to $23 from $30.
09/20/17
LOOP
09/20/17
NO CHANGE
Target $23
LOOP
Hold
Bed Bath & Beyond price target lowered to $23 from $35 at Loop Capital
Loop Capital analyst Anthony Chukumba, who said in a prior first take research note last night that Bed Bath & Beyond's Q2 results and guidance were "much worse" than expected, is now calling the quarter "disastrous" in a new note. The analyst, who is disappointed in the company's "vague" turnaround plan and lack of intention to speed up store closings, cut his price target on the stock to $23 from $35 and keeps a Hold rating on the shares.
DESP Despegar.com

CELC Celcuity
$14.29

14.289 (1,428,900.00%)

ZLAB Zai Lab

KRYS Krystal Biotech

TODAY'S FREE FLY STORIES

20:45
10/16/17
10/16
20:45
10/16/17
20:45
General news
Breaking General news story  »

Minneapolis Federal…

20:25
10/16/17
10/16
20:25
10/16/17
20:25
Conference/Events
Federal Reserve Bank of Minneapolis participates in a dinner meeting »

Minneapolis Federal…

JNJ

Johnson & Johnson

$136.12

-0.31 (-0.23%)

, UNH

UnitedHealth

$193.20

0.68 (0.35%)

20:25
10/16/17
10/16
20:25
10/16/17
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

JNJ

Johnson & Johnson

$136.12

-0.31 (-0.23%)

UNH

UnitedHealth

$193.20

0.68 (0.35%)

GS

Goldman Sachs

$242.41

3.88 (1.63%)

MS

Morgan Stanley

$48.94

0.64 (1.33%)

CSX

CSX

$52.84

0.01 (0.02%)

PGR

Progressive

$48.98

0.31 (0.64%)

CMA

Comerica

$75.34

-0.21 (-0.28%)

GWW

Grainger

$182.36

1.31 (0.72%)

HOG

Harley-Davidson

$46.57

-0.05 (-0.11%)

SNV

Synovus

$46.65

0.01 (0.02%)

TTS

Tile Shop

$8.45

0.1 (1.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 17

    Oct

  • 17

    Oct

  • 17

    Oct

  • 17

    Oct

  • 17

    Oct

  • 17

    Oct

  • 17

    Oct

  • 17

    Oct

  • 17

    Oct

  • 17

    Oct

  • 17

    Oct

  • 22

    Oct

  • 23

    Oct

  • 27

    Oct

  • 29

    Oct

  • 30

    Oct

  • 06

    Nov

  • 15

    Nov

  • 24

    Jan

MSBI

Midland States

$33.03

-0.07 (-0.21%)

19:02
10/16/17
10/16
19:02
10/16/17
19:02
Hot Stocks
Midland States to acquire Alpine Bancorporation in roughly $181M deal »

Midland States Bancorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

  • 15

    Nov

MYL

Mylan

$38.18

0.23 (0.61%)

, AGN

Allergan

$198.41

-7.11 (-3.46%)

18:46
10/16/17
10/16
18:46
10/16/17
18:46
Hot Stocks
Mylan CEO: 'Pleased' with court ruling on Allergan's Restasis patents »

Mylan (MYL) announced…

MYL

Mylan

$38.18

0.23 (0.61%)

AGN

Allergan

$198.41

-7.11 (-3.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 20

    Oct

  • 23

    Oct

  • 01

    Nov

  • 06

    Nov

  • 03

    Dec

NFLX

Netflix

$202.68

3.19 (1.60%)

18:44
10/16/17
10/16
18:44
10/16/17
18:44
Hot Stocks
Netflix says seeing steady growth, great success for streaming »

Says still has bias…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 22

    Oct

PCG

PG&E

$53.43

-4.29 (-7.43%)

18:42
10/16/17
10/16
18:42
10/16/17
18:42
Hot Stocks
PG&E sees restoring service to all electric customers in CA affected by fires »

PG&E said that more…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Nov

  • 05

    Nov

  • 05

    Nov

CYTR

CytRx

$0.38

-0.0142 (-3.64%)

18:29
10/16/17
10/16
18:29
10/16/17
18:29
Hot Stocks
CytRx granted listing extension pending results of stockholder vote »

CytRx 's request for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

EADSY

Airbus

$22.75

-0.07 (-0.31%)

, BDRBF

Bombardier

$1.88

0.03 (1.62%)

18:27
10/16/17
10/16
18:27
10/16/17
18:27
Hot Stocks
Airbus and Bombardier announce C Series partnership »

Airbus (EADSY) and…

EADSY

Airbus

$22.75

-0.07 (-0.31%)

BDRBF

Bombardier

$1.88

0.03 (1.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IMDZ

Immune Design

$10.10

-0.85 (-7.76%)

18:16
10/16/17
10/16
18:16
10/16/17
18:16
Conference/Events
Immune Design to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 08

    Nov

PG

Procter & Gamble

$93.14

0.1 (0.11%)

18:15
10/16/17
10/16
18:15
10/16/17
18:15
Hot Stocks
Trian: P&G board election results 'too close to call' »

Trian Fund Management,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

AMZN

Amazon.com

$1,006.34

3.4 (0.34%)

18:14
10/16/17
10/16
18:14
10/16/17
18:14
Periodicals
NJ leaders offer up to $7B in tax incentives to lure Amazon to Newark, WSJ says »

New Jersey Governor Chris…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 16

    Oct

  • 17

    Oct

  • 22

    Oct

  • 26

    Oct

BDRBF

Bombardier

$1.88

0.03 (1.62%)

, EADSY

Airbus

$22.75

-0.07 (-0.31%)

18:09
10/16/17
10/16
18:09
10/16/17
18:09
Periodicals
Bombardier in talks with Airbus over CSeries jet unit JV, WSJ reports »

Bombardier (BDRBF) is in…

BDRBF

Bombardier

$1.88

0.03 (1.62%)

EADSY

Airbus

$22.75

-0.07 (-0.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IPXL

Impax

$19.95

-0.85 (-4.09%)

17:55
10/16/17
10/16
17:55
10/16/17
17:55
Hot Stocks
Impax jumps 6% in after-hours after WSJ says Amneal deal near »

Shares of Impax are up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Nov

IPXL

Impax

$19.95

-0.85 (-4.09%)

17:51
10/16/17
10/16
17:51
10/16/17
17:51
Periodicals
Impax and Amneal close to merger pact, WSJ says »

Impax Laboratories and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Nov

AGII

Argo Group

$62.90

-0.25 (-0.40%)

17:36
10/16/17
10/16
17:36
10/16/17
17:36
Hot Stocks
Argo Group provides preliminary Q3 loss estimate »

Argo Group announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FDEF

First Defiance Financial

$53.65

-0.25 (-0.46%)

17:34
10/16/17
10/16
17:34
10/16/17
17:34
Earnings
First Defiance Financial reports Q3 EPS 92c, consensus 89c »

Reports Q3 NII $ $25.0M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

BRO

Brown & Brown

$48.97

-0.42 (-0.85%)

17:33
10/16/17
10/16
17:33
10/16/17
17:33
Earnings
Brown & Brown reports Q3 EPS 53c, consensus 50c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

ORIG

Ocean Rig UDW

$26.18

0.51 (1.99%)

17:31
10/16/17
10/16
17:31
10/16/17
17:31
Hot Stocks
Ocean Rig holder BlueMountain intends to recommend company hire advisers »

Ocean Rig UDW holder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$202.68

3.19 (1.60%)

, IMDZ

Immune Design

$10.10

-0.85 (-7.76%)

17:31
10/16/17
10/16
17:31
10/16/17
17:31
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS:…

NFLX

Netflix

$202.68

3.19 (1.60%)

IMDZ

Immune Design

$10.10

-0.85 (-7.76%)

SAVE

Spirit Airlines

$33.47

-0.33 (-0.98%)

UNH

UnitedHealth

$193.20

0.68 (0.35%)

BMI

Badger Meter

$50.80

-0.6 (-1.17%)

SONC

Sonic

$24.80

0.42 (1.72%)

ABEO

Abeona Therapeutics

$16.70

0.6 (3.73%)

VICL

Vical

$2.86

0.04 (1.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 16

    Oct

  • 17

    Oct

  • 17

    Oct

  • 17

    Oct

  • 22

    Oct

  • 23

    Oct

  • 08

    Nov

  • 17

    Oct

FDC

First Data

$18.01

0.39 (2.21%)

17:28
10/16/17
10/16
17:28
10/16/17
17:28
Hot Stocks
First Data CAO sells 3,996 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 30

    Oct

ROSG

Rosetta Genomics

$1.00

-0.0479 (-4.57%)

17:28
10/16/17
10/16
17:28
10/16/17
17:28
Syndicate
Breaking Syndicate news story on Rosetta Genomics »

Rosetta Genomics files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HRS

Harris

$135.90

-0.66 (-0.48%)

17:27
10/16/17
10/16
17:27
10/16/17
17:27
Hot Stocks
Harris awarded $100M government contract modification »

Harris Corp., Clifton,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$259.75

-0.99 (-0.38%)

17:26
10/16/17
10/16
17:26
10/16/17
17:26
Hot Stocks
Boeing awarded $240.2M government contract »

The Boeing Co., Oklahoma…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

PI

Impinj

$34.98

-0.71 (-1.99%)

17:22
10/16/17
10/16
17:22
10/16/17
17:22
Hot Stocks
Impinj COO sells 7,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

  • 14

    Nov

  • 15

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.